Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7579 in advanced solid tumors
NCT03182257Phase 1Terminated
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2017
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of ono-7579 in solid tumor (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Incidence, nature and severity of Adverse Events up to 28 days, Clinically significant changes in physical examinations up to 28 days and 3 more. Started Jul 2017; status: terminated.
02
Drugs
ono-7579
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03182257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03182257.